Revenue Misses Estimates, Cytek Biosciences Reports Wider Q1 Net Loss
CTKB sits 81% above its 52-week low of $2.37.
Summary
Cytek Biosciences reported Q1 revenue growth of 6% year-over-year to $44.14 million, which slightly missed analyst estimates of $44.33 million. The company posted a net loss of $18.9 million for the quarter, and its adjusted EBITDA loss widened compared to the prior year. This continues a trend of increasing net losses, following the significant increase reported in the fiscal year 2025 10-K. Despite the slight revenue miss and widening losses, Cytek reaffirmed its full-year 2026 revenue guidance of $205 million to $212 million. Traders will likely focus on the ongoing profitability challenges and widening losses, despite the top-line growth and reaffirmed guidance, watching for signs of improved operational efficiency in future quarters.
At the time of this announcement, CTKB was trading at $4.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $632.5M. The 52-week trading range was $2.37 to $6.18. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.